Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogs

Citations Over TimeTop 22% of 1991 papers

Abstract

A series of novel imidazoquinoxalinones and their aza analogues were prepared by the cyclization of o-amino(1H-imidazol-1-yl)aryls and heteroaryls with carbonyldiimidazole. The compounds were screened for inhibition of Type I and Type IV phosphodiesterases (PDE's) and evaluated for their vasorelaxant and positive inotropic activities in vitro. In general, compounds having potent PDE inhibitory activity also possessed good inotropic and vasodilator activity, although linear correlations between these activities could not be established.

Related Papers

• → Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families(2002)45 cited
• → FR226807: a potent and selective phosphodiesterase type 5 inhibitor(2001)19 cited
• → Cardiovascular activity of WIN 65579, a novel inhibitor of cyclic GMP phosphodiesterase 5(1998)10 cited
• → Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction(2010)
• → EFFICACY OF COMBINATION OF ASPIRIN WITH PHOSPHODIESTERASE TYPE 5 INHIBITORS IN PHOSPHODIESTERASE TYPE 5 INHIBITORS NON-RESPONDERS ERECTILE DYSFUNCTION PATIENTS(2021)